AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
August 18, 2021- In the atogepant Phase 3 ADVANCE trial, participants experienced a significant reduction in migraine and headache days across 12 weeks of treatment¹
-
August 09, 2021- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe
-
August 04, 2021- Upadacitinib (30 mg, once daily) monotherapy demonstrated significantly greater rates of skin clearance improvement and itch reduction compared to dupilumab (300 mg, every other week) monotherapy at 16 weeks[1]
-
July 30, 2021- Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis; Adjusted Diluted EPS of $3.11
-
July 29, 2021-- 6.7 million adults in the U.S. are living with spasticity across a variety of neurologic conditions
-
July 27, 2021- Extension builds on partnership established in 2014, extended in 2018
-
July 25, 2021- If approved, AGN-190584 is expected to be the first eye drop for the treatment of presbyopia, the eye's reduced ability to focus on near objects
-
July 23, 2021- DALVANCE® is the first and only single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth
-
July 21, 2021- This is the sixth BTD granted for venetoclax as AbbVie continues to show ongoing commitment across blood cancers including tough to treat myeloid malignancies
-
July 20, 2021- Data presentations highlight Phase 3 GEMINI 1 trial results on the safety and efficacy of investigational AGN-190584 (pilocarpine 1.25%) as a potential novel treatment for presbyopia, a common and progressive eye condition that reduces the eye's ability to focus on near objects
-
June 29, 2021- Significantly more upadacitinib-treated (15 mg or 30 mg, once daily) patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to patients on placebo at one-year (week 52) (p<0.001)[1]
-
June 25, 2021- Positive opinion based on three global Phase 3 pivotal studies evaluating the safety and efficacy of RINVOQ (15 mg or 30 mg, once daily) used with or without topical corticosteroids in adults and adolescents with moderate to severe atopic dermatitis[1],[2]
-
June 17, 2021
-
June 12, 2021- All-oral, once-daily, chemotherapy-free, fixed-duration ibrutinib plus venetoclax (I+V) combination met its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC); I+V reduced the risk of disease progression or death by 78% compared to chlorambucil plus obinutuzumab (C+O)
-
June 11, 2021- Four-year follow-up analysis of Phase 3 CLL14 trial (median follow-up 52.4 months), continues to demonstrate longer progression-free survival (PFS) after fixed-duration venetoclax plus obinutuzumab compared to fixed duration chlorambucil plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL)
-
June 08, 2021BRAND UNVEILS 'SEE YOURSELF' DOCUMENTARY STYLE CONTENT SERIES HIGHLIGHTING THE PEOPLE WHO GET TREATED WITH BOTOX® COSMETIC AND THEIR REASON WHY
-
June 07, 2021- The fixed-duration combination met the primary endpoint of complete response rate at 56% among patients with previously untreated CLL, 70 years old or younger
-
June 04, 2021- With up to seven years of data, progression-free and overall survival benefits continue to be observed with first-line single-agent IMBRUVICA treatment in CLL patients including selected patients with or without high-risk genomic features
-
June 02, 2021- In Crohn's disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1]
-
June 02, 2021- In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2]
-
June 02, 2021- Long-term data from the Phase 3 SELECT-COMPARE trial show that continuous treatment with RINVOQ (upadacitinib, 15 mg, once-daily) plus MTX maintained rates of clinical remission and low disease activity through three years in adults with rheumatoid arthritis[1]
-
May 26, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts
-
May 25, 2021-- VENCLYXTO® (venetoclax) in combination with a hypomethylating agent is a new regimen approved by the European Commission (EC) for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy [1]
-
May 25, 2021- First presentation of three-year data from Phase 3 SELECT-COMPARE study assessing long-term efficacy and safety of RINVOQ® (upadacitinib) versus HUMIRA® (adalimumab) in patients with rheumatoid arthritis (RA)
-
May 24, 2021- In the ADVANCE trial, risankizumab (SKYRIZI) met co-primary endpoints of clinical remission and endoscopic response compared to placebo at 12 weeks in patients with intolerance or inadequate response to conventional and/or biologic therapy[1]
-
May 19, 2021-- 43 abstracts on six investigational and approved medicines across 12 cancer types to be presented at both meetings
-
May 10, 2021-- Acquisition adds Rapid Acoustic Pulse technology platform for improvement in appearance of cellulite in the buttocks and thighs --
-
April 30, 2021- Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95
-
April 27, 2021- New analyses of Phase 3 ARTEMIS studies provide further insights on duration and biodegradation of DURYSTA™ (bimatoprost intracameral implant)
-
April 23, 2021- Positive opinion based on data from the VIALE-A and M14-358 trials, which evaluated the safety, efficacy and pharmacokinetics of VENCLYXTO in combination with hypomethylating agents in adult patients with AML
-
April 07, 2021- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1]
-
April 07, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine to be presented at the Clinical Trials Plenary Session; study was also only headache topic to earn Merit of Distinction in 2021
-
April 01, 2021Revolutionary, Clinically Proven Product Addresses Multi-Factorial Causes & Symptoms of Neck Aging
-
April 01, 2021- In SELECT-PsA 1, RINVOQ™ (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis[1]
-
March 31, 2021
-
March 30, 2021- If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine[1]
-
February 25, 2021- If approved, this is expected to be the first eye drop to treat presbyopia
-
February 24, 2021- HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis[1]
-
February 22, 2021- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p<0.001)[1]
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
